Trial Profile
Administration of Tumor-Associated Antigen (TAA)-Specific Cytotoxic T-Lymphocytes to Patients With Active or Relapsed Hodgkin or Non-Hodgkin Lymphoma
Status:
Active, no longer recruiting
Phase of Trial:
Phase I
Latest Information Update: 13 Apr 2022
Price :
$35
*
At a glance
- Drugs Zedenoleucel (Primary) ; Azacitidine; T lymphocyte cell therapies
- Indications Diffuse large B cell lymphoma; Hodgkin's disease; Mantle-cell lymphoma; Non-Hodgkin's lymphoma; T-cell lymphoma
- Focus Adverse reactions
- Acronyms TACTAL
- 04 Apr 2022 Planned End Date changed from 1 May 2027 to 27 Sep 2027.
- 04 Apr 2022 Status changed from recruiting to active, no longer recruiting.
- 09 Mar 2021 Planned End Date changed from 1 Jan 2026 to 1 May 2027.